13.98
21-二月-25 16:45:00
15 分钟延时
股票
-0.33
-2.31%
今日范围
13.57 - 14.80
ISIN
N/A
来源
NASDAQ
Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
05 1月 2021 08:00:02 条件 Nasdaq GlobeNewswire